

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 19956

**Title:** Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

**Reviewer's code:** 03017483

**Reviewer's country:** China

**Science editor:** Jing Yu

**Date sent for review:** 2015-05-28 16:34

**Date reviewed:** 2015-06-10 14:48

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

The PI3K/AKT/mTOR pathway is highly activated in gastric cancer, so targeting this pathway for cancer therapy attracts great interests. In this review, first each components of this pathway was generally introduced, as well as the upstream signals and downstream effects. Second, various types of single or dual pathway inhibitors in preclinical or clinical trials for gastric cancer treatment were summarized. Finally, the predictive biomarkers to facilitate more personalized PI3K/Akt/mTOR pathway targeted gastric cancer therapy were briefly introduced. This review emphasizes on gastric cancer to summarize the dysregulation of PI3K/AKT/mTOR pathway and this pathway targeted cancer therapy. It is presented in an intelligible fashion and is written logically and smoothly. However, there are some minor errors need to be corrected before it is accepted for publication. The paragraph on page 15 is about the studies of perifosine on gastric cancer. The "eLF4E" should be "eIF4E". And this reference is "Liang S, Guo R, Zhang Z, Liu D, Xu H, Xu Z, Wang X, Yang L. Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. *Oncol Rep.* 2013 Jun;29(6):2422-30." Moreover, the



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

reference for the combination of perifosine and miR-27a inhibitors should be number 92.